Accuray Incorporated (NASDAQ:ARAY) CFO Ali Pervaiz Sells 8,195 Shares

Accuray Incorporated (NASDAQ:ARAY) CFO Ali Pervaiz sold 8,195 shares of the business’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $2.85, for a total value of $23,355.75. Following the transaction, the chief financial officer now owns 405,160 shares in the company, valued at $1,154,706. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Accuray Stock Down 3.2 %

NASDAQ:ARAY opened at $2.76 on Thursday. The company has a current ratio of 1.79, a quick ratio of 1.00 and a debt-to-equity ratio of 3.16. Accuray Incorporated has a 12 month low of $1.81 and a 12 month high of $4.30. The firm has a fifty day simple moving average of $3.52 and a 200-day simple moving average of $3.36.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings results on Wednesday, August 9th. The medical equipment provider reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.04). The firm had revenue of $118.29 million for the quarter, compared to analyst estimates of $121.50 million. Accuray had a negative return on equity of 17.98% and a negative net margin of 2.07%. During the same period in the prior year, the firm posted ($0.04) EPS. As a group, research analysts expect that Accuray Incorporated will post -0.02 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ARAY. TheStreet raised Accuray from a “d+” rating to a “c-” rating in a report on Monday, June 5th. StockNews.com cut shares of Accuray from a “buy” rating to a “hold” rating in a research note on Wednesday, August 16th.

Institutional Investors Weigh In On Accuray

A number of institutional investors and hedge funds have recently modified their holdings of ARAY. BlackRock Inc. raised its position in Accuray by 1.5% during the 1st quarter. BlackRock Inc. now owns 7,749,993 shares of the medical equipment provider’s stock worth $25,651,000 after buying an additional 114,036 shares during the last quarter. Archon Capital Management LLC increased its stake in shares of Accuray by 2.8% in the fourth quarter. Archon Capital Management LLC now owns 6,104,738 shares of the medical equipment provider’s stock worth $12,759,000 after acquiring an additional 167,747 shares during the period. Neuberger Berman Group LLC raised its holdings in shares of Accuray by 8.0% during the third quarter. Neuberger Berman Group LLC now owns 5,246,160 shares of the medical equipment provider’s stock worth $10,905,000 after purchasing an additional 387,772 shares during the last quarter. Vanguard Group Inc. lifted its position in Accuray by 2.7% during the first quarter. Vanguard Group Inc. now owns 4,505,531 shares of the medical equipment provider’s stock valued at $14,913,000 after purchasing an additional 117,354 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Accuray by 17.6% in the second quarter. Renaissance Technologies LLC now owns 3,671,907 shares of the medical equipment provider’s stock valued at $7,197,000 after purchasing an additional 549,523 shares during the last quarter. Institutional investors and hedge funds own 69.58% of the company’s stock.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.